B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. (PubMed, J Natl Compr Canc Netw) - Sep 18, 2026 - "Pirtobrutinib (a highly selective noncovalent BTK inhibitor) and CAR T-cell therapy (brexucabtagene autoleucel or lisocabtagene maraleucel) have emerged as effective treatment options for refractory or progressive disease after prior treatment with covalent BTK inhibitors. This selection from NCCN Guidelines for B-Cell Lymphomas focuses on the recommendations for the diagnosis and treatment of MCL."
Clinical guideline • Journal • NCCN guideline • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin's Lymphoma • Oncology • TP53
|
|
Aditi Saha; Alaa AlTahan; Andrew D Zelenetz; Ann S LaCasce; Babis Andreadis; Bhagirathbhai Dholaria; Boyu Hu; Christopher R Kelsey; Daniel Landsburg; Erin Reid; Francisco Hernandez-Ilizaliturri; Hema Sundar; Jeremy S Abramson; Joseph Tuscano; Julie M Vose; Justin Kline; Kenneth B Roberts; L Elizabeth Budde; Leo I Gordon; Lode J Swinnen; Luis E Fayad; Manali Kamdar; Marcus Messmer; Mary Dwyer; Megan Lim; Nancy L Bartlett; Naoyuki G Saito; Paolo F Caimi; Peter Riedell; Praveen Ramakrishnan; Priyanka Pophali; Rachel Rabinovitch; Ranjana H Advani; Rebecca King; Sameh Gaballa; Stephen D Smith; Susan Krivacic; Sven deVos; Thomas M Habermann; Yasmin Karimi; Yazeed Sawalha
|